Shots:
The US FDA has granted conditional approval to Exzolt Cattle-CA1 to prevent & treat New World screwworm (Cochliomyia hominivorax) larvae (myiasis) & cattle fever tick (Rhipicephalus microplus)
Exzolt Cattle-CA1, a systemic fluralaner pour-on available in 1L & 5L presentations, is approved for use in beef cattle (≥2mos.) & replacement dairy heifers (<20mos.), with US availability…
Shots:
Merck Animal Health has reported data on Bovillis Nasalgen-C (Lyophilisate & Solvent for Suspension; intranasal vaccination) for the prevention of bovine coronavirus in veal calves at Vlaamse Buiatriecongres’25
Data was presented from a study titled “Intranasal vaccination against bovine coronavirus significantly improves production parameters in cross-bred veal calves: Results from a randomized field trial”,…
Shots:
The US FDA has approved Exzolt (fluralaner oral solution) to treat & control northern fowl mites (Ornithinyssus sylviarum) in chickens
Exzolt is a parasiticide that targets the nervous system of northern fowl mites, killing those that ingest a blood meal, while remaining safe for laying hens & replacement chickens
Exzolt, available in 1L &…
Shots:
The US FDA has approved Bravecto Quantum (Fluralaner for Extended-Release Injectable Suspension), a once-yearly injectable for flea and tick protection in dogs, will be available in U.S. veterinary clinics by Aug, 2025
Bravecto Quantum kills adult fleas and controls flea and tick infestations (Ixodes scapularis, Dermacentor variabilis, Rhipicephalus sanguineus) for 12 mos., and Amblyomma…
Shots:
The CVMP has recommended Nobivac L6 & Nobivac LoVo L6 for the active immunization of dogs against leptospirosis; EC’s decision expected by Q3’25
The vaccine protects against 6 Leptospira serovars: Canicola, Copenhageni, Bratislava, Bananal/Lianguang, Icterohaemorrhagiae, & Grippotyphosa, preventing mortality, renal carriage, renal lesions, & urinary excretion while reducing infection & clinical signs
Nobivac L6…
Shots:
The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025
Mometamax Single has shown favorable efficacy, with 80.5% resolution of clinical signs in dogs vs 19.6% with PBO
Mometamax Single is a single-dose in-clinic treatment for otitis…
Shots:
Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary use
Collaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug delivery
AmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force…
Shots:
The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3B
This quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS'…
Shots:
The US FDA approved 8 NDAs and 1 BLA in January 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 9 novel products in 2023
In January 2023, the major highlights drugs were Rykindo (risperidone) approval for schizophrenia and bipolar 1 disorder, Brenzavvy (bexagliflozin) for type…
The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4B
The third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…

